Clinical Trials Logo

Filter by:
NCT ID: NCT06454383 Recruiting - Clinical trials for Stage IV Pancreatic Cancer AJCC v8

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Start date: May 13, 2024
Phase: Phase 1
Study type: Interventional

This phase Ib trial tests the safety, side effects, and best dose of leflunomide in combination with gemcitabine in treating patients with pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and cannot be removed by surgery (unresectable). Improving the effectiveness of gemcitabine without increasing side effects could lead to a greater impact for pancreatic cancer patients' survival and quality of life. Gemcitabine is commonly used as a first-line chemotherapy treatment for pancreatic cancer. Leflunomide is a drug approved for use against rheumatoid arthritis that is being looked at as a cancer treatment option. It has shown promising results when combined with gemcitabine. Giving gemcitabine in combination with leflunomide may be safe and effective in treating patients with advanced unresectable pancreatic cancer.

NCT ID: NCT06454344 Recruiting - Inflammation Clinical Trials

The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The overall purpose of this study is to understand the role of disrupted sleep in the association of exposure to early life adversity (adverse childhood experiences (ACEs)) with vascular endothelial (dys)function. In Aim 1 (The Iowa ACEs and Sleep Cohort Study), the investigators will utilize a cross-sectional cohort design with a state-of-the-art translational approach. Participants will be recruited to objectively characterize the degree to which lower sleep quality and quantity contribute to ACEs-related endothelial dysfunction, inflammation, and oxidative stress in young adults using: 1. rigorous at home sleep monitoring using 7-nights of wrist actigraphy and 2 nights of home-based polysomnography to objectively measure sleep quality (sleep efficiency, wakefulness after sleep onset and sleep depth), and total sleep duration, 2. in vivo assessment of endothelial function via flow-mediated dilation testing, and 3. in vitro determination of endothelial cell inflammation and oxidative stress from biopsied endothelial cells. This study to achieve this Aim. In Aim 2, approximately 70 eligible participants from Aim 1 (The Iowa ACEs and Sleep Cohort Study) will then be randomized to either a 6-week behavioral sleep intervention (cognitive behavioral therapy for insomnia) or a wait-list control to determine the mechanistic contribution of sleep disruption to vascular dysfunction in young adults with moderate-to-high exposure to adverse childhood experiences (ACEs). Following the intervention, participants will again complete: 1. rigorous at home sleep monitoring using 7-nights of wrist actigraphy and 2 nights of home-based polysomnography to objectively measure sleep quality (sleep efficiency, wakefulness after sleep onset and sleep depth), and total sleep duration, 2. in vivo assessment of endothelial function via flow-mediated dilation testing, and 3. in vitro determination of endothelial cell inflammation and oxidative stress from biopsied endothelial cells.

NCT ID: NCT06454058 Enrolling by invitation - Fertility Clinical Trials

Association Between Euploid Embryo Grade and Maternal Age

Start date: June 14, 2024
Phase:
Study type: Observational

Background: Advanced maternal age (AMA) is associated with a reduction in live birth rate (LBR) after ART cycles. The main reason for this reduction is the lower number of oocytes aspirated, the number of developing embryos and the low number of euploid embryos available for transfer. The impact of age on success rates after the transfer of an euploid embryo has been a matter of discussion, with a recent meta-analysis showing a reduction in LBR after the transfer of an euploid blastocyst to women of AMA (1). There could be many reasons for this reduced LBR but they can be categorized into two broad categories - the uterus (including the mother's health) and the embryo (including the oocyte and the sperm). It is possible that factors associated with reduced embryo quality would manifest in a lower embryo grade.

NCT ID: NCT06454019 Enrolling by invitation - Clinical trials for Behavioral Economics

Phone Outreach Nudges Among Individuals Losing Medicaid Coverage

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

In May 2023, Covered California, California's ACA marketplace, implemented its automatic enrollment program for individuals losing Medicaid coverage, as defined by Senate Bill 260. If individuals are found eligible for subsidized marketplace coverage, individuals will be automatically enrolled in the lowest cost silver plan available to them, but individuals must still take action to confirm their plan or pay their first month's premium. To identify whether the phone outreach is the effective outreach strategy to increase take-up in this population, Covered California implemented this intervention. The results of this evaluation will inform operational and budgeting decisions.

NCT ID: NCT06453993 Active, not recruiting - Esophageal Cancer Clinical Trials

Temporal Variation in Exhaled Volatile Organic Compounds in Esophageal Cancer Patients

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether exhaled breath can be used to detect and monitor esophageal cancer.

NCT ID: NCT06453980 Recruiting - Clinical trials for Mild Cognitive Impairment

Multimodal Investigation of Neural Plasticity

miniSTIM
Start date: May 13, 2024
Phase: N/A
Study type: Interventional

This study will evaluate the effects of a form of non-invasive brain stimulation on brain functioning and memory in cognitively intact older adults (healthy controls, HC) and in those with mild cognitive impairment (MCI).

NCT ID: NCT06453915 Not yet recruiting - Clinical trials for Positron Emission Tomography

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Start date: July 2024
Phase: Early Phase 1
Study type: Interventional

Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk factors with Alzheimer's, such as diabetes and hypertension, and studies have linked MASLD to increased risks of cognitive decline and ADRD. Mouse-model studies suggest that chronic liver inflammation in MASLD can induce neuroinflammation and accelerate Alzheimer's pathology, highlighting the importance of studying the liver-brain connection to identify new therapeutic targets for ADRD. The goal of this research is to develop a practical PET imaging method using 18F-FDG to simultaneously assess liver and brain inflammation in patients with MASLD-related ADRD. This approach leverages dynamic FDG-PET scanning and advanced tracer kinetic modeling to quantify glucose transport, overcoming limitations of traditional imaging methods that cannot noninvasively assess chronic liver inflammation. The new method aims to enable comprehensive imaging of liver-brain inflammation crosstalk, validated against the 18F-DPA-714 radiotracer. Success in this project could provide a valuable imaging tool for linking liver inflammation with neuroinflammation and cognitive decline, advancing clinical research and potentially uncovering new pathways for ADRD treatment

NCT ID: NCT06453824 Recruiting - Clinical trials for Safety and Tolerability

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

Start date: May 17, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to test the safety and drug effects of MDI-2517 when given once in healthy volunteers.

NCT ID: NCT06453694 Not yet recruiting - Optic Neuritis Clinical Trials

Efgartigimod for the Treatment of Acute Optic Neuritis

PET-AON
Start date: October 2024
Phase: Phase 2
Study type: Interventional

The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation). The main questions it aims to answer are: - Is it feasible to use efgartigimod alfa for optic neuritis? - Is it feasible to run a larger trial testing efgartigimod alfa in optic neuritis? - Does efgartigimod alfa work better than placebo in improving how quickly and how much vision returns? Participants will: - have their vision and blood tested - be asked questions about their vision - will receive standard of care treatment with steroids regardless of whether they are receiving efgartigimod alfa or not - will have periodic visits over 6 months

NCT ID: NCT06453629 Recruiting - Clinical trials for Autism Spectrum Disorder

RCT to Evaluate Social Skills in Children With Autism Using VR Technology (SoCaVR)

SoCaVR
Start date: May 31, 2024
Phase: N/A
Study type: Interventional

The goal of this randomized clinical trial is to compare and learn about Virtual Reality (VR) in children with autism/Autistic children. The main question it aims to answer is: • Does the Floreo VR clinical product show clinical improvement in autism symptoms? Participants will engage the VR product for twice a week for twelve weeks. They will be randomized to either the Floreo Clinical Product or a VR Control group experience. Researchers will compare the two groups to see if there is an effect on learning specific skills and behaviors.